title: [Erythropoietin and neuroprotection].
abstract: Erythropoietin (Epo) has long been recognised for its role in the control of erythropoiesis and therefore in the treatment of anemia including anemia of prematurity. The erythropoietin receptor (Epo-R) though is expressed in many other organs including the CNS. This review focuses on the role of erythropoietin during the development of the CNS and its potential role as a neuroprotective agent. Epo-R is expressed in many different cellules of the CNS during development including neural progenitor cells, neurons, astrocytes and oligodendrocytes. In the event of hypoxia CNS cells respond with increase of erythropoietin release with subsequent stimulation of neurogenesis through Epo-R on neural progenitor cells. In an Epo-R knock-out model therefore cerebral development is severely impaired. In models of hypoxia-ischemia exogenous Epo has been shown to reduce lesion size and improve structural and functional recovery. Human studies are emerging using Epo as a neuroprotective agent both for the term infant with hypoxia-ischemia as well as for the extremely preterm infant.
authors: Service du développement et de la croissance, Département de l'enfant et de l'adolescence, Hôpitaux Universitaires de Genève, Suisse. alexandra.chatagner@unige.ch
authors: A
authors: A
authors: Chatagner
authors: P S
authors: PS
authors: Hüppi
authors: R
authors: R
authors: Ha-Vinh Leuchter
authors: S
authors: S
authors: Sizonenko
mesh_terms: D001921:Brain / Q000254:growth & development; D004921:Erythropoietin / Q000627:therapeutic use*; D055786:Gene Knockout Techniques; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000235:genetics; D018696:Neuroprotective Agents / Q000627:therapeutic use; D017467:Receptors, Erythropoietin / Q000172:deficiency / Q000235:genetics / Q000502:physiology
chemical_list: D018696:Neuroprotective Agents; D017467:Receptors, Erythropoietin; D004921:Erythropoietin